CSIMarket Company Name, Ticker, Customers, else..
 
Processa Pharmaceuticals Inc   (NASDAQ: PCSA)
Other Ticker:  
 
 
Price: $0.4320 $-0.02 -3.550%
Day's High: $0.462 Week Perf: -4.23 %
Day's Low: $ 0.43 30 Day Perf: -28.12 %
Volume (M): 49 52 Wk High: $ 3.31
Volume (M$): $ 21 52 Wk Avg: $1.38
Open: $0.45 52 Wk Low: $0.42



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 3
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Processa Pharmaceuticals Inc
Processa Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of drug therapies for patients with unmet medical needs. The company primarily focuses on developing drugs for the treatment of rare diseases and conditions. Processa Pharmaceuticals aims to improve patient outcomes and quality of life by bringing innovative therapies to market. They conduct clinical trials, collaborate with research institutions, and seek regulatory approvals to bring their drugs to market. Their ultimate goal is to become a leading provider of effective and accessible treatments for rare diseases.


   Company Address: 7380 Coca Cola Drive Hanover 21076 MD
   Company Phone Number: 776-3133   Stock Exchange / Ticker: NASDAQ PCSA


Customers Net Income fell by PCSA's Customers Net Profit Margin fell to

-11.44 %
8.5 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AKRO   -4.94%    
IRWD   -4.22%    
JAGX   -49.58%    
REGN   -3.56%    
VKTX   -2.47%    
VRTX        3.69% 
• View Complete Report
   



Stocks on the Move

Processa Pharmaceuticals Inc Faces Recent Stock Decline Amidst Pharmaceutical Industry Challenges

Published Tue, Jul 9 2024 9:58 AM UTC

Processa Pharmaceuticals Inc Shares Trail Market Performance Amidst Recent DeclineProcessa Pharmaceuticals Inc has experienced a decline in share performance over the past week, trailing the overall market trends. However, it is worth noting that over the past 12 months, the company s shares have outperformed the market. This decline comes amidst various developments and new...
Processa Pharmaceuticals Inc

Processa Pharmaceuticals Inc Shows Significant Improvement, Reducing Operating Loss by $2.5 Million in Q2 2023



As the fiscal period of April to June 2023 draws to a close, various businesses in the Major Pharmaceutical Preparations sector have released their financial results. Among them, Processa Pharmaceuticals Inc stands out with notable performance. With an operating loss of $-2.714465 million for the period ending June 30, 2023, the company has shown significant progress compared to the previous year's corresponding period, where the operating loss amounted to $-5.171748 million. This optimistic trend has bolstered confidence in Processa Pharmaceuticals Inc, leaving analysts eager to explore the impact these positive results might have on the company's future prospects.
Improvement in Operating Loss:
Processa Pharmaceuticals Inc's latest financial results reveal an operating loss reduction of approximately $2.5 million compared to the same period last year. This significant improvement can be attributed to the company's strategic initiatives, showing its ability to navigate challenges effectively. By reducing the operating loss, Processa Pharmaceuticals Inc has successfully moved towards achieving better financial stability.
Processa Pharmaceuticals Inc

Processa Pharmaceuticals Inc Faces Deepening Financial Woes with $-4.1 Million Operating Deficit in Q1 2023

Processa Pharmaceuticals Inc is a company in the major pharmaceutical preparations industry that has been under close observation recently due to its financial performance. In the first quarter of 2023, the company reported an operating deficit of $-4.105535 million, which is a cause for concern for industry observers.
What is alarming is that the company has not disclosed any revenue so far, and as such, the observers are unable to determine the extent of the problem. However, by comparing its operating deficit with its performance in the first quarter of 2021, where it recorded a deficit of $-3.524894 million, it is clear that the company is struggling.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com